nVerses Capital’s Cabaletta Bio CABA Stock Holding History

nVerses Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,000	Closed	-$14.2K	–	134
2024 Q3	$14.2K	Buy	+3,000	New	+$17.4K	0.01%	852

Other funds holding CABA

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

nVerses Capital's CABA Position: Q4 2024 in Review

nVerses Capital sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 3,000 shares — an estimated $14.2K sold.

nVerses Capital first reported a position in CABA in Q3 2024 and held it in 1 quarter. The position peaked at $14.2K in Q3 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

nVerses Capital reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 3,000 Cabaletta Bio shares in Q4 2024, an estimated $14.2K.
nVerses Capital first reported a position in Cabaletta Bio in Q3 2024 and held it in 1 quarter.
nVerses Capital's Cabaletta Bio position peaked at $14.2K in Q3 2024.
108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.